Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.60 +1.3%	$1.64	$0.99 ▼ $6.26	$146.34M	2.74	1.56 million shs	554,309 shs
MGTX MeiraGTx	$7.85 +3.8%	$7.65	$3.85 ▼ $8.98	$631.53M	1.25	530,928 shs	193,289 shs
SIGA Siga Technologies	$8.75 -0.3%	$7.11	$4.95 ▼ $9.80	$626.59M	0.94	476,107 shs	471,392 shs
TSHA Taysha Gene Therapies	$2.87	$2.61	$1.05 ▼ $3.31	$616.07M	0.98	2.88 million shs	1.69 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-2.47%	-7.60%	-3.66%	-11.24%	-67.69%
MGTX MeiraGTx	-0.26%	-9.35%	-13.00%	+49.41%	+79.57%
SIGA Siga Technologies	+0.11%	0.00%	+28.18%	+50.34%	-0.73%
TSHA Taysha Gene Therapies	+1.06%	-5.28%	+13.44%	+0.70%	+25.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.1143 of 5 stars	3.5	4.0	0.0	0.0	0.8	0.6
MGTX MeiraGTx	4.4632 of 5 stars	3.5	4.0	4.8	1.9	2.5	0.6
SIGA Siga Technologies	2.0794 of 5 stars	0.0	2.0	0.0	2.4	0.8	3.1
TSHA Taysha Gene Therapies	3.384 of 5 stars	4.5	2.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	801.79% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	205.73% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	188.70% Upside

Current Analyst Ratings Breakdown

Latest CABA, MGTX, SIGA, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
MGTX MeiraGTx	$33.28M	18.98	N/A	N/A	$0.04 per share	196.25
SIGA Siga Technologies	$138.72M	4.52	$0.83 per share	10.48	$2.92 per share	3.00
TSHA Taysha Gene Therapies	$8.33M	73.96	N/A	N/A	$1.16 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	N/A
MGTX MeiraGTx	-$147.79M	-$2.04	N/A	20.66	N/A	-415.39%	-314.44%	-63.28%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.74	7.00	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	N/A

Latest CABA, MGTX, SIGA, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGTX MeiraGTx	-$0.52	-$0.48	+$0.04	-$0.48	$8.00 million	$3.69 million
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	4.78	4.78
MGTX MeiraGTx	26.29	0.88	1.51
SIGA Siga Technologies	N/A	10.09	8.52
TSHA Taysha Gene Therapies	0.17	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
MGTX MeiraGTx	67.48%
SIGA Siga Technologies	55.40%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
MGTX MeiraGTx	7.50%
SIGA Siga Technologies	1.95%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	91.46 million	81.18 million	Optionable
MGTX MeiraGTx	300	80.45 million	74.41 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

CABA, MGTX, SIGA, and TSHA Headlines

Recent News About These Companies

Critical Analysis: Taysha Gene Therapies (NASDAQ:TSHA) and Targeted Medical Pharma (OTCMKTS:TRGM)

August 19 at 3:13 AM | americanbankingnews.com

FY2025 Earnings Forecast for TSHA Issued By Chardan Capital

August 19 at 2:29 AM | marketbeat.com

FY2025 Earnings Estimate for TSHA Issued By Chardan Capital

August 18 at 2:31 AM | americanbankingnews.com

Cantor Fitzgerald Issues Negative Forecast for TSHA Earnings

August 17, 2025 | marketbeat.com

FY2025 EPS Forecast for Taysha Gene Therapies Cut by Analyst

August 16, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst Upgrade

August 15, 2025 | marketbeat.com

Wells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00

August 15, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00

August 15, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00

August 14, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

August 13, 2025 | msn.com

4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...

August 13, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

August 13, 2025 | marketbeat.com

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

August 13, 2025 | finance.yahoo.com

XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 13, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

August 13, 2025 | msn.com

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028

August 13, 2025 | msn.com

What's Next: Taysha Gene Therapies's Earnings Preview

August 13, 2025 | benzinga.com

Taysha Gene Therapies Advances Rett Syndrome Trials

August 12, 2025 | tipranks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Taysha Gene Therapies, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, MGTX, SIGA, and TSHA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.60 +0.02 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.31%)

As of 05:47 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

MeiraGTx NASDAQ:MGTX

$7.85 +0.29 (+3.84%)

Closing price 04:00 PM Eastern

Extended Trading

$7.84 0.00 (-0.06%)

As of 04:20 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Siga Technologies NASDAQ:SIGA

$8.75 -0.03 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.75 0.00 (0.00%)

As of 06:00 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Taysha Gene Therapies NASDAQ:TSHA

$2.87 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 04:59 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time